Effect of tumour necrosis factor α blockade on bone metabolism in chronic inflammatory joint diseases
| Autor: | Manuel Haro Liger, José Luis Casals Sánchez, Francisco Javier Aguilar del Rey, Rita Pérez González, Rosa García Portales, José Rodríguez Andreu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Bone density Anti-Inflammatory Agents Gastroenterology Etanercept Bone remodeling Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Osteoprotegerin Bone Density Internal medicine medicine Humans Spondylitis Ankylosing Longitudinal Studies Prospective Studies 030212 general & internal medicine BASDAI Aged 030203 arthritis & rheumatology Ankylosing spondylitis Tumor Necrosis Factor-alpha business.industry Arthritis Psoriatic RANK Ligand Adalimumab Middle Aged medicine.disease Infliximab Treatment Outcome Endocrinology Rheumatoid arthritis Chronic Disease Female Bone Remodeling business BASFI Biomarkers medicine.drug |
| Zdroj: | Medicina Clínica (English Edition). 147:56-62 |
| ISSN: | 2387-0206 |
| DOI: | 10.1016/j.medcle.2016.09.005 |
| Popis: | Background and objective To evaluate the effect of anti-TNF treatments on bone mineral density (BMD), bone remodelling markers (BRM) and receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) in patients with chronic inflammatory joint diseases. Methods A longitudinal prospective study was performed under clinical practice conditions on 31 patients diagnosed of rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis who had received treatment with anti-TNF alpha drugs for one year. BMD, OPG and RANKL soluble form (sRANKL) were studied at the onset and end of the study. During the study (0, 3, 6, 9 and 12 month), disease activity (SDAI, BASDAI and CRP), functional capacity (HAQ, BASFI), BRM and vitamin D were studied. Results BMD was not modified after one year of treatment. The patients who took corticosteroids had a mean bone mass loss of 3% in the lumbar spine (±1.6, p = .02). In regards to the BRM, did not experience significant changes over the course of the study. Disease activity, both SDAI ( p = .002) and BASDAI ( p = .002), decreased. OPG was maintained without changes during the year of treatment while both the sRANKL (0.28 ± 0.22, p = .013) and sRANKL/OPG ratio significantly decreased (0.04 ± 0.03, p = .031). Conclusion The patients being treated with anti-TNF did not present with a significant loss of DMO during the study (one year), at the same time experiencing an improvement in disease activity. This protection has been clearer in the responding patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect